

U.S.S.N. 08/323,060

Filed: October 14, 1994

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 50-1868.

In the Claims

7. (Amended) [The method of claim 2 wherein the inhibitor is] A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising administering to the patient a compound in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma, wherein the compound is an antibody that inhibits protein C anticoagulant [an antibody to protein C].

8. (Three times amended) [The method of claim 7 wherein the inhibitor is] A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising administering to the patient a compound in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma, wherein the compound is an antibody that inhibits protein C anticoagulant, and wherein the compound is administered systemically, further comprising the step of topically administering a coagulant at the site of bleeding.

9. (Amended) [The method of claim 8] A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising administering to the patient a compound in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma, wherein the

562364v1

CMRFP 128
078617/00137

U.S.S.N. 08/323,060

Filed: October 14, 1994

AMENDMENT AND RESPONSE TO OFFICE ACTION

compound is administered systemically further comprising the step of topically administering a coagulant at the site of bleeding, wherein the compound is an antibody that inhibits protein C anticoagulant, and wherein the topically administered coagulant is selected from the group consisting of thrombin in a dosage of between approximately 1000 and 10,000 units and tissue factor in a dosage of between approximately 0.1 and 10 mg.

20. (Amended) [The method of claim 3 wherein the inhibitor] A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising administering to the patient a compound in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma, wherein the compound is a monoclonal antibody immunoreactive with protein C and [blocking] blocks protein C activation, and wherein the compound is administered systemically.

21. (Amended) [he method of claim 20] A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising administering to the patient a compound in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma, wherein the compound is a monoclonal antibody immunoreactive with protein C and blocks protein C activation, wherein the compound is administered systemically and wherein the compound is HPC-4, deposited with the American Type Culture Collection, Rockville, MD and assigned ATCC No. 9892.

568364v1

CMRPF 128
078617/00137